Philippe Thompson-Leduc

Vice President
Philippe Thompson-Leduc

Education

M.Sc., epidemiology, Laval University; B.Sc., biology, Concordia University

Summary of Experience

Mr. Thompson-Leduc is an epidemiologist specializing in pharmacoepidemiology and health economics and outcomes research (HEOR). He has more than a decade of experience designing, leading, and disseminating real-world evidence studies to inform clinical, regulatory, and reimbursement decision making. Mr. Thompson-Leduc’s methodological expertise includes retrospective database analyses, medical chart review studies, surveys, systematic literature reviews, and meta-analyses. His research has focused primarily on hematological conditions and viral diseases, with broader experience across oncology, autoimmune, respiratory, and infectious disease areas. Mr. Thompson-Leduc’s work spans both academic and community care settings and examines treatment patterns, clinical outcomes, health care resource utilization, and economic burden using large administrative claims databases and real-world clinical data. His findings have informed regulatory decision making, including support for a label expansion at the US Food and Drug Administration (FDA) for a medical device manufacturer. Mr. Thompson-Leduc’s research has been published widely in journals such as Critical Care Medicine, Academic Medicine, CNS Drugs, Cancer Medicine, The Journal of Rheumatology, and the Journal of Medical Economics. He has presented his work at scientific conferences, including meetings of the American Society of Clinical Oncology (ASCO), the American Society of Hematology (ASH), the International Society for Pharmacoeconomics and Outcomes Research (ISPOR), and the International Conference on Pharmacoepidemiology and Therapeutic Risk Management (ICPE). At Analysis Group, Mr. Thompson-Leduc leads multidisciplinary teams in support of life sciences companies and medical device manufacturers that seek to address complex clinical, economic, and regulatory research questions.